ATE460671T1 - Identifikation von arzneimittel gegen mykobakterien - Google Patents

Identifikation von arzneimittel gegen mykobakterien

Info

Publication number
ATE460671T1
ATE460671T1 AT03751127T AT03751127T ATE460671T1 AT E460671 T1 ATE460671 T1 AT E460671T1 AT 03751127 T AT03751127 T AT 03751127T AT 03751127 T AT03751127 T AT 03751127T AT E460671 T1 ATE460671 T1 AT E460671T1
Authority
AT
Austria
Prior art keywords
rv2027c
devr
devs
degree
single domain
Prior art date
Application number
AT03751127T
Other languages
English (en)
Inventor
Jaya S Tyagi
Deepak K Saini
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Application granted granted Critical
Publication of ATE460671T1 publication Critical patent/ATE460671T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03751127T 2002-10-16 2003-10-16 Identifikation von arzneimittel gegen mykobakterien ATE460671T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41883702P 2002-10-16 2002-10-16
PCT/IB2003/004555 WO2004036224A2 (en) 2002-10-16 2003-10-16 Screening method

Publications (1)

Publication Number Publication Date
ATE460671T1 true ATE460671T1 (de) 2010-03-15

Family

ID=32107981

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03751127T ATE460671T1 (de) 2002-10-16 2003-10-16 Identifikation von arzneimittel gegen mykobakterien

Country Status (7)

Country Link
US (1) US7566550B2 (de)
EP (1) EP1554586B1 (de)
CN (1) CN100554966C (de)
AT (1) ATE460671T1 (de)
AU (1) AU2003269346A1 (de)
DE (1) DE60331669D1 (de)
WO (1) WO2004036224A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795978B2 (en) * 2007-06-22 2014-08-05 The Uab Research Foundation Modulating latency and reactivation of Mycobacterium tuberculosis
KR101574332B1 (ko) * 2008-06-17 2015-12-08 재단법인 한국파스퇴르연구소 항감염성 화합물
WO2012002239A1 (ja) * 2010-06-29 2012-01-05 独立行政法人産業技術総合研究所 ハロゲン化物の検出剤、並びにそれを検出する方法及び検出センサー
EP3050565A1 (de) * 2015-01-27 2016-08-03 Ecole Polytechnique Fédérale de Lausanne (EPFL) Benzimidazolschwefelderivate zur Vorbeugung oder Behandlung von Tuberkulose
WO2016182819A2 (en) * 2015-05-05 2016-11-17 William Marsh Rice University Identifying ligands from bacterial sensors
WO2020202188A1 (en) * 2019-03-29 2020-10-08 Indian Institute Of Science In-vitro processes for screening candidate molecules
EP3953686A4 (de) * 2019-04-09 2022-12-21 Agency for Science, Technology and Research Markierungsfreie detektion von mycobakterien mittels oberflächenverstärkter raman-spektroskopie
CN115312136B (zh) * 2022-06-20 2025-10-28 军事科学院军事医学研究院环境医学与作业医学研究所 一种环境双酚类污染物生态风险的评价模型的构建方法和评价方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975280A (en) * 1989-01-23 1990-12-04 Ethyl Corporation Bioerodable sustained release implants
US6043045A (en) * 1996-09-12 2000-03-28 The Scripps Research Institute Screening methods for the identification of novel antibiotics
US6162627A (en) 1998-03-19 2000-12-19 University Of Medicine And Dentistry Of New Jersey Methods of identifying inhibitors of sensor histidine kinases through rational drug design
GB0030368D0 (en) * 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
GB2398302B (en) 2002-02-08 2005-10-19 All India Inst Med A process for identifying a novel target for use for the development of therapeutic modalities and drugs effective against tuberculosis

Also Published As

Publication number Publication date
US7566550B2 (en) 2009-07-28
WO2004036224A3 (en) 2004-09-02
AU2003269346A8 (en) 2004-05-04
EP1554586B1 (de) 2010-03-10
EP1554586A2 (de) 2005-07-20
WO2004036224A2 (en) 2004-04-29
DE60331669D1 (de) 2010-04-22
US20040209319A1 (en) 2004-10-21
CN100554966C (zh) 2009-10-28
AU2003269346A1 (en) 2004-05-04
CN1754100A (zh) 2006-03-29

Similar Documents

Publication Publication Date Title
Wenzel et al. Proteomic response of Bacillus subtilis to lantibiotics reflects differences in interaction with the cytoplasmic membrane
Yamaguchi et al. Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor
WO2004065561A3 (en) Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
Garate et al. NAD (P) H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33ING1b
NO20053114L (no) Astma og allergisk inflammasjonsmodulatorer.
ATE403719T1 (de) Konditionelles selex
WO2008127274A3 (en) Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
DE60331669D1 (de) Identifikation von Arzneimittel gegen Mykobakterien
ATE432358T1 (de) Kolorimetrische substrate, kolorimetrische sensoren und verwendungsverfahren
Ding et al. Five tyrosines and two serines in human albumin are labeled by the organophosphorus agent FP-biotin
Suazo et al. Metabolic labeling with an alkyne probe reveals similarities and differences in the prenylomes of several brain-derived cell lines and primary cells
ATE328112T1 (de) Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
DE602004015791D1 (de) Screening-Verfahren zur Identifizierung von Tau-Protein modulierenden Substanzen.
Liu et al. Denervation-induced activation of the standard proteasome and immunoproteasome
BR0011437A (pt) Métodos de triagem para alterar proteìnas do ritmo circadiano
Yang et al. Mass spectrometric quantitation of tubulin acetylation from pepsin-digested rat brain tissue using a novel stable-isotope standard and capture by anti-peptide antibody (SISCAPA) method
Tsutsumi et al. The potential role of transient receptor potential type A 1 as a mechanoreceptor in human periodontal ligament cells
Ciotti et al. The binding landscape of a partially-selective isopeptidase inhibitor with potent pro-death activity, based on the bis (arylidene) cyclohexanone scaffold
DE60029413D1 (de) Enzymatische messung von mycophenolsäure
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
Puschner et al. Calmodulin-dependent protein kinases mediate calcium-induced slow motility of mammalian outer hair cells
DE60122141D1 (de) Assay zur detektion der transferaseenzymaktivität beim screening von medikamenten
Asteggiano et al. Phosphatidyl inositol‐4, 5‐bisphosphate bound to bovine cardiac Na+/Ca2+ exchanger displays a MgATP regulation similar to that of the exchange fluxes
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties